| 2008 | A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2020 | A phase II study of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma | ANNALS OF HEMATOLOGY |
| 2016 | A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas | ANNALS OF ONCOLOGY |
| 2002 | A phase II study of gemcitiabine monotherapy in breast cancer patients refractory to anthracycline and taxane
| CANCER RESEARCH AND TREATMENT |
| 2001 | A Phase II Study of Genexol® ( paclitaxel ) in Metastatic Breast Cancer
| CANCER RESEARCH AND TREATMENT |
| 2006 | A Phase II Study of Infusional 5-Fluorouracil and Low-Dose Leucovorin with Docetaxel for Advanced Gastric Cancer | ONCOLOGY |
| 2022 | A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11) | CLINICAL CANCER RESEARCH |
| 2023 | A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)
| CANCERS |
| 2016 | A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial | LEUKEMIA & LYMPHOMA |
| 2008 | A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer. | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
| 2021 | A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
| CANCER MEDICINE |
| 2016 | A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis | RADIOTHERAPY AND ONCOLOGY |
| 2007 | A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status
| BRITISH JOURNAL OF CANCER |
| 2014 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. | CLINICAL CANCER RESEARCH |
| 2002 | A Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13)
| EUROPEAN JOURNAL OF CANCER |
| 2022 | A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13) | EUROPEAN JOURNAL OF CANCER |
| 2019 | A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
| CANCER RESEARCH AND TREATMENT |
| 2004 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer
| ANNALS OF ONCOLOGY |
| 2014 | A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer | CANCER CHEMOTHERAPY AND PHARMACOLOGY |
